Abstract
Material and methods: Following a PubMed search the most important and largest studies of preventive drug therapy for hereditary breast and ovarian cancer were selected and are summarized here.
Results and discussion: In addition to selective estrogen receptor modulators (SERMs) a good preventive effect could also been shown for aromatase inhibitors, in addition to a significantly reduced side effect profile. However, the results need to be confirmed in larger patient cohorts especially for women with a mutation in BRCA1/2.
Aims: This article gives an overview of the currently investigated drug options for the prevention of breast cancer, especially for hereditary forms and cases with a proven genetic background.
Background: The preventive drug therapy for mutation carriers (currently BRCA1 and 2 positive women) is becoming increasingly more important. Prophylactic surgery of the breast can be very distressing and could be supplemented or even replaced by appropriate preventive pharmacological measures.
| Translated title of the contribution | BRCA mutations and preventive drug therapy: Target groups, substance and timing |
|---|---|
| Original language | German |
| Pages (from-to) | 753-758 |
| Number of pages | 6 |
| Journal | Gynakologe |
| Volume | 47 |
| Issue number | 10 |
| DOIs | |
| State | Published - 14 Oct 2014 |
